SynthesisFrontiers in immunology2025
BioBERT-powered synergy: advanced bibliometric and molecular insights into prostate cancer bone metastasis.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cervical Skip Metastases and Extensive Central Venous Thrombosis as the Initial Presentation of High-Grade Prostate Adenocarcinoma With Discordant PI-RADS 3 Findings: A Case Report and Diagnostic Challenge.Clinical case reports · 2026Article
- Global research trends at the intersection of climate change and parasitic diseases: a systematic bibliometric research (2000-2025).Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer (PC) is a leading cause of male cancer mortality, with bone metastasis (BM) being a frequent and debilitating complication. Despite therapeutic advancements, the molecular mechanisms underlying BM remain poorly understood. This study aims to bridge this gap by integrating bibliometric analysis with bioinformatics to provide a comprehensive overview of the academic trends and molecular profiles associated with prostate cancer bone metastasis (PCBM). Methods: We conducted a bibliometric analysis to identify key contributors in PCBM research from 2004 to 2024 with advanced tools like BioBERT to mine gene and disease entities from the abstracts of relevant articles. Gene expression data from GSE32269 was analyzed to identify differentially expressed genes (DEGs), followed by enrichment analyses for biological functions and pathways. Results: The bibliometric review showed an increasing trend in research output, focusing on therapeutic strategies and biomarkers. Bioinformatics analysis revealed various DEGs, significantly enriched in immune response and cell adhesion pathways. Semantic relationship analysis highlighted potential shared pathways between genes and diseases, offering clues for novel immunotherapy targets. Conclusion: By integrating bibliometric analysis with bioinformatics, this study provides new insights into PCBM. Specifically, our findings emphasize the impact of reprogramming on immune cells and its role in reshaping the tumor microenvironment to support cancer cells' evasion of immune surveillance and promotion of metastasis. These results suggest that targeting immune checkpoints and innovative combination therapies may be critical directions for improving outcomes in prostate cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.